| . | Total (n = 19) . | Early ART <7 d (n = 10) . | Late ART >7 d (n = 9) . |
|---|---|---|---|
| Age, y | 33 (28–41) | 29.5 (25–35.7) | 36 (32–45) |
| Cisgender men | 19 (100) | 10 (100) | 9 (100) |
| HIV status | |||
| Previously diagnosed without ART | 14 (73.7) | 6 (60) | 8 (88.9) |
| Newly diagnosed | 5 (26.3) | 4 (40) | 1 (11.1) |
| Time HIV diagnosis, y | 0 (0–10) | 0 (0–0.25) | 8 (0.5–12) |
| Last CD4 count, cells/mm3 | 236 (64–339) | 227.5 (98.5–285.5) | 236 (46.5–425.5) |
| HIV-1 RNA viral load, copies/mL | 74 334 (15 575–233 437) | 69 559 (9193.7–201 124.5) | 78 191 (18 129–251 466.5) |
| Additional conditions | |||
| Hepatitis B | 1 (5.3) | 0 (0) | 1 (11.1) |
| Hepatitis C | 2 (10.5) | 1 (10) | 1 (11.1) |
| Syphilis | 3 (15.8) | 3 (30) | 0 (0) |
| Anal warts | 1 (5.3) | 1 (10) | 0 (0) |
| History of mpox vaccination | 0 (0) | 0 (0) | 0 (0) |
| Mpox rash presentation | |||
| Peak number of skin lesions | 30 (20–50) | 42.5 (22.5–50) | 27.5 (15.5–82.5) |
| Rash duration, d | 28 (20.2–43.7) | 25 (18–37.5) | 32.5 (22–48.7) |
| Severity skin scorea | |||
| Mild | 5 (26.3) | 2 (20) | 3 (33.3) |
| Moderate | 8 (42.1) | 5 (50) | 3 (33.3) |
| Severe | 2 (10.5) | 1 (10) | 1 (11.1) |
| Very severe | 1 (5.3) | 0 (0) | 1 (11.1) |
| Missing data | 3 (15.8) | 2 (20) | 1 (11.1) |
| IRIS mpox | 2 (10.5) | 1 (10) | 1 (11.1) |
| Outcomes | |||
| Outpatient | 17 (89.4) | 10 (100) | 7 (77.7) |
| Deaths | 0 (0) | 0 (0) | 0 (0) |
| Hospitalization | 2b (10.5) | 0 (0) | 2 (22.2) |
| Lost to follow-up | 2 (10.5) | 1 (10) | 1 (11.1) |
| Retention in care | 17 (89.4) | 9 (90) | 8 (88.8) |
| . | Total (n = 19) . | Early ART <7 d (n = 10) . | Late ART >7 d (n = 9) . |
|---|---|---|---|
| Age, y | 33 (28–41) | 29.5 (25–35.7) | 36 (32–45) |
| Cisgender men | 19 (100) | 10 (100) | 9 (100) |
| HIV status | |||
| Previously diagnosed without ART | 14 (73.7) | 6 (60) | 8 (88.9) |
| Newly diagnosed | 5 (26.3) | 4 (40) | 1 (11.1) |
| Time HIV diagnosis, y | 0 (0–10) | 0 (0–0.25) | 8 (0.5–12) |
| Last CD4 count, cells/mm3 | 236 (64–339) | 227.5 (98.5–285.5) | 236 (46.5–425.5) |
| HIV-1 RNA viral load, copies/mL | 74 334 (15 575–233 437) | 69 559 (9193.7–201 124.5) | 78 191 (18 129–251 466.5) |
| Additional conditions | |||
| Hepatitis B | 1 (5.3) | 0 (0) | 1 (11.1) |
| Hepatitis C | 2 (10.5) | 1 (10) | 1 (11.1) |
| Syphilis | 3 (15.8) | 3 (30) | 0 (0) |
| Anal warts | 1 (5.3) | 1 (10) | 0 (0) |
| History of mpox vaccination | 0 (0) | 0 (0) | 0 (0) |
| Mpox rash presentation | |||
| Peak number of skin lesions | 30 (20–50) | 42.5 (22.5–50) | 27.5 (15.5–82.5) |
| Rash duration, d | 28 (20.2–43.7) | 25 (18–37.5) | 32.5 (22–48.7) |
| Severity skin scorea | |||
| Mild | 5 (26.3) | 2 (20) | 3 (33.3) |
| Moderate | 8 (42.1) | 5 (50) | 3 (33.3) |
| Severe | 2 (10.5) | 1 (10) | 1 (11.1) |
| Very severe | 1 (5.3) | 0 (0) | 1 (11.1) |
| Missing data | 3 (15.8) | 2 (20) | 1 (11.1) |
| IRIS mpox | 2 (10.5) | 1 (10) | 1 (11.1) |
| Outcomes | |||
| Outpatient | 17 (89.4) | 10 (100) | 7 (77.7) |
| Deaths | 0 (0) | 0 (0) | 0 (0) |
| Hospitalization | 2b (10.5) | 0 (0) | 2 (22.2) |
| Lost to follow-up | 2 (10.5) | 1 (10) | 1 (11.1) |
| Retention in care | 17 (89.4) | 9 (90) | 8 (88.8) |
Data are presented as No. (%) or median (IQR).
Abbreviations: ART, antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome.
a<25 lesions, mild; 25–99 lesions, moderate; 100–250 lesions, severe; >250 lesions, very severe.
bOne individual was hospitalized for IRIS-related mpox, while another was hospitalized for suspected neuroinfection unrelated to mpox.
| . | Total (n = 19) . | Early ART <7 d (n = 10) . | Late ART >7 d (n = 9) . |
|---|---|---|---|
| Age, y | 33 (28–41) | 29.5 (25–35.7) | 36 (32–45) |
| Cisgender men | 19 (100) | 10 (100) | 9 (100) |
| HIV status | |||
| Previously diagnosed without ART | 14 (73.7) | 6 (60) | 8 (88.9) |
| Newly diagnosed | 5 (26.3) | 4 (40) | 1 (11.1) |
| Time HIV diagnosis, y | 0 (0–10) | 0 (0–0.25) | 8 (0.5–12) |
| Last CD4 count, cells/mm3 | 236 (64–339) | 227.5 (98.5–285.5) | 236 (46.5–425.5) |
| HIV-1 RNA viral load, copies/mL | 74 334 (15 575–233 437) | 69 559 (9193.7–201 124.5) | 78 191 (18 129–251 466.5) |
| Additional conditions | |||
| Hepatitis B | 1 (5.3) | 0 (0) | 1 (11.1) |
| Hepatitis C | 2 (10.5) | 1 (10) | 1 (11.1) |
| Syphilis | 3 (15.8) | 3 (30) | 0 (0) |
| Anal warts | 1 (5.3) | 1 (10) | 0 (0) |
| History of mpox vaccination | 0 (0) | 0 (0) | 0 (0) |
| Mpox rash presentation | |||
| Peak number of skin lesions | 30 (20–50) | 42.5 (22.5–50) | 27.5 (15.5–82.5) |
| Rash duration, d | 28 (20.2–43.7) | 25 (18–37.5) | 32.5 (22–48.7) |
| Severity skin scorea | |||
| Mild | 5 (26.3) | 2 (20) | 3 (33.3) |
| Moderate | 8 (42.1) | 5 (50) | 3 (33.3) |
| Severe | 2 (10.5) | 1 (10) | 1 (11.1) |
| Very severe | 1 (5.3) | 0 (0) | 1 (11.1) |
| Missing data | 3 (15.8) | 2 (20) | 1 (11.1) |
| IRIS mpox | 2 (10.5) | 1 (10) | 1 (11.1) |
| Outcomes | |||
| Outpatient | 17 (89.4) | 10 (100) | 7 (77.7) |
| Deaths | 0 (0) | 0 (0) | 0 (0) |
| Hospitalization | 2b (10.5) | 0 (0) | 2 (22.2) |
| Lost to follow-up | 2 (10.5) | 1 (10) | 1 (11.1) |
| Retention in care | 17 (89.4) | 9 (90) | 8 (88.8) |
| . | Total (n = 19) . | Early ART <7 d (n = 10) . | Late ART >7 d (n = 9) . |
|---|---|---|---|
| Age, y | 33 (28–41) | 29.5 (25–35.7) | 36 (32–45) |
| Cisgender men | 19 (100) | 10 (100) | 9 (100) |
| HIV status | |||
| Previously diagnosed without ART | 14 (73.7) | 6 (60) | 8 (88.9) |
| Newly diagnosed | 5 (26.3) | 4 (40) | 1 (11.1) |
| Time HIV diagnosis, y | 0 (0–10) | 0 (0–0.25) | 8 (0.5–12) |
| Last CD4 count, cells/mm3 | 236 (64–339) | 227.5 (98.5–285.5) | 236 (46.5–425.5) |
| HIV-1 RNA viral load, copies/mL | 74 334 (15 575–233 437) | 69 559 (9193.7–201 124.5) | 78 191 (18 129–251 466.5) |
| Additional conditions | |||
| Hepatitis B | 1 (5.3) | 0 (0) | 1 (11.1) |
| Hepatitis C | 2 (10.5) | 1 (10) | 1 (11.1) |
| Syphilis | 3 (15.8) | 3 (30) | 0 (0) |
| Anal warts | 1 (5.3) | 1 (10) | 0 (0) |
| History of mpox vaccination | 0 (0) | 0 (0) | 0 (0) |
| Mpox rash presentation | |||
| Peak number of skin lesions | 30 (20–50) | 42.5 (22.5–50) | 27.5 (15.5–82.5) |
| Rash duration, d | 28 (20.2–43.7) | 25 (18–37.5) | 32.5 (22–48.7) |
| Severity skin scorea | |||
| Mild | 5 (26.3) | 2 (20) | 3 (33.3) |
| Moderate | 8 (42.1) | 5 (50) | 3 (33.3) |
| Severe | 2 (10.5) | 1 (10) | 1 (11.1) |
| Very severe | 1 (5.3) | 0 (0) | 1 (11.1) |
| Missing data | 3 (15.8) | 2 (20) | 1 (11.1) |
| IRIS mpox | 2 (10.5) | 1 (10) | 1 (11.1) |
| Outcomes | |||
| Outpatient | 17 (89.4) | 10 (100) | 7 (77.7) |
| Deaths | 0 (0) | 0 (0) | 0 (0) |
| Hospitalization | 2b (10.5) | 0 (0) | 2 (22.2) |
| Lost to follow-up | 2 (10.5) | 1 (10) | 1 (11.1) |
| Retention in care | 17 (89.4) | 9 (90) | 8 (88.8) |
Data are presented as No. (%) or median (IQR).
Abbreviations: ART, antiretroviral therapy; IRIS, immune reconstitution inflammatory syndrome.
a<25 lesions, mild; 25–99 lesions, moderate; 100–250 lesions, severe; >250 lesions, very severe.
bOne individual was hospitalized for IRIS-related mpox, while another was hospitalized for suspected neuroinfection unrelated to mpox.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
